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ABSTRACT
Background: Erosive lichen planus (LP) of 
the soles is a rare variant of LP, characterized 
by chronic, painful, and disabling plantar 
ulcerations. Herein, we report a case with 
complete healing following treatment with 
systemic steroids. Case report: A 38-year-old 
woman was referred with painful and disabling 
erosive bilateral plantar LP, which she had 
experienced for 6 weeks. A 1 mg/kg/day, oral 
prednisone therapy led to rapid improvement 
and complete healing within 3 weeks, with a 
sustained result under a low dose maintenance 
therapy. Discussion: Ulcerative plantar LP is 
significantly known to be unresponsive to 
several topical and systemic therapies. Surgical 
excision and grafting is the treatment of 
choice. Systemic steroids are reported to have 
inefficient or partial results; both on cutaneous 
healing and on maintenance of the result. Our 
patient achieved complete cicatrisation with a 
sustained result of 3 months under a low dose 
of prednisone (5 mg/day).
Keywords: erosive lichen planus; lichen planus; 
prednisone; soles; systemic steroids
INTRODUCTION
Erosive, or ulcerative, lichen planus (LP) is a rare 
variant of LP; mainly affecting the oral cavity 
and genitalia. Plantar location is less common, 
with only a few reported cases in the literature.1,2
Erosive LP of the soles is characterized by 
painful erosions leading to limited mobility 
and disability. Due to its rarity, its treatment 
remains nonstandardized and difficult.3 This 
study presents a female patient with erosive LP 
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of the soles whose condition rapidly improved 
with systemic steroids treatment.
CASE REPORT
A healthy 38-year-old woman was referred 
with painful and disabling erosive bilateral 
plantar LP, which she had experienced for 
6 weeks. The patient reported that she had a 
5-year history of recurrent episodes of pruritic 
bilateral plantar keratoderma that had preceded 
the plantar ulcerations with progressive toenail 
pigmentation. There was no malady in her 
background and family history, and there was 
no history of drug intake before the lesions 
had appeared. Upon referral, the patient was in 
extreme pain, could not walk without crutches, 
and spent much of each day in bed. Before 
this study, she had previously received several 
treatments (topical steroids under occlusion, 
topical salicylic acid, and systemic methotrexate) 
without success. 
On clinical examination, there was bilateral, 
cracked plantar keratoderma. On the internal 
plantar archs, there were bilateral ill-defined, 
exsudative, red erosions of 6 cm by 4 cm on 
the right foot, and of 3 cm by 2 cm on the left 
foot (Figure 1). The surrounded skin appeared 
slightly erythematous and pigmented. There was 
bilateral palmar keratoderma and longitudinal 
melanonychia of all toenails (Figure 2). No 
more anomalies of neither the fingernails 
nor the toenails were observed. Cutaneous 
examination was otherwise normal; including 
oral and genital mucosa, and the scalp. Routine 
laboratory parameters were normal and 
markers for hepatitis B and C were negative. 
Histopathological findings on a cutaneous 
biopsy were consistent with the diagnosis of LP, 
showing epidermal hyperplasia with elongated 
rete redges, apoptotic keratinocytes (Civatte 
bodies), and band-like lymphocytic infiltration 
in the superficial dermal area, with exocytosis 
toward the basal layer (Figure 3). The patient was 
given 1 mg/kg/day (90 mg/day) of prednisone. 
This treatment produced a rapid clinical 
improvement, with a significant reduction of 
pain at the end of the first week, and complete 
healing within 3 weeks (Figure 4). At 4 weeks 
of therapy, prednisone was gradually reduced 
by 10 mg a week. The patient was examined 
Figure 1. Bilateral erosions on internal plantar archs.
Figure 2. Longitudinal melanonychia of toenails.
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at 3 months of therapy, and was fully mobile 
with no signs of recurrence. Unfortunately, the 
patient was lost to follow-up during treatment 
with 5 mg/day of prednisone.
DISCUSSION
Erosive plantar LP is an unusual and aggressive 
variant of LP.4 Few cases have been reported 
in the literature since the first description by 
Friedman in 1921.5 It is an adult-onset disease 
and women are more affected than men.6 It is 
characterized by chronic, painful, disabling, 
large and superficial ulcers which show irregular 
form, inflammation, and an exsudative base. 
It can be difficult to diagnose ulcerative LP of 
the soles when it appears as an isolated finding. 
However, it is usually associated with typical 
cutaneous lesions of LP, cicatricial alopecia, 
erosive LP of the oral mucosa or genitalia, and 
nail abnormalities; especially atrophy of the 
nail bed, anonychia, pterygium formation, and 
toenail loss.4,5,7 This patient had only palmar 
keratoderma and longitudinal melanonychia 
of the toenails, which has not been reported 
previously in plantar erosive lichen. Atypical 
locations have been reported in a few cases, such 
as the pretibial zone and flexural areas.1,8
Several authors have drawn attention to the 
association of ulcerative LP and autoimmune 
diseases, such as autoimmune thyroiditis, 
associated with primary biliary cirrhosis and 
Sjögren’s syndrome.9,10 However, this study 
did not investigate autoimmune diseases for 
the referred patient. Ulcerative plantar lichen 
should be differentiated from severe eczema, 
Figure 3. Epidermal hyperplasia, elongated rete ridges, 
and bandlike lymphocytic infiltration in the superficial 
dermal area.
Figure 4. Complete healing of the erosions within 3 weeks 
under systemic steroids.
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localized bullous pemphigoid on the soles, and 
plantar erythrodysesthesia; a relatively common 
side effect of some types of chemotherapy, 
such as gefitinib.11 Ulcerative LP of soles is 
significantly known to be unresponsive to 
several therapies: topical and systemic steroids, 
etretinate, chloroquine, dapsone, cyclosporine 
A, and thalidomide, which give only partial and 
temporary benefits with frequent recurrences.12
Since the first reported treatment, surgical 
excision followed by skin grafting seems to be 
the only treatment that has proven its efficacy, 
and the reported grafted cases were completely 
successful, with no recurrence during a 
follow-up period of 18 months to 26 years.7
The combination of systemic cyclosporine and 
surgical excision, followed by skin grafting, 
is also recommended, since cyclosporine is 
excellent for the management of inflammation; 
allowing the successful outcome of the skin 
graft.4 Topical tacrolimus has also been reported 
to have produced rapid clinical improvement 
in a few studies. In one study, 95% healing 
was reported after 4 weeks,2 whilst in another, 
complete healing was reported within a few 
weeks; however, the latter study had complete 
remission during a follow-up period of 
more than 2 years.3 The use of systemic 
corticosteroids in the treatment of LP have 
been reported in rare cases. Eisman and Orteu 
prescribed a combination of prednisolone 
(30 mg/day) and acitretin (20 mg/day) for 4 
months without significant benefit,8 whilst in 
another case, authors reported poor results with 
systemic corticosteroids.2 In this current patient, 
oral prednisone was immediately favorable, 
leading to complete healing of ulcerations after 
3 weeks. Quality of life and mobility were also 
significantly enhanced. This study obtained a 
sustained result of 3 months under a low dose 
of prednisone (5 mg/day). However, this study 
is unable to evaluate long-term efficacy of oral 
steroids in the absence of long-term patient 
follow-up.
CONCLUSION
Despite many treatment modalities used to treat 
ulcerative LP, it is still considered a resistant 
disease. We obtained an effective response with 
oral prednisone; however, further studies are 
required to assess this result and to evaluate its 
long term benefit.
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